AFX 221

Drug Profile

AFX 221

Alternative Names: AFX-221; Molindone - Afecta Pharmaceuticals; NGI-221

Latest Information Update: 24 Jun 2008

Price : $50

At a glance

  • Originator Afecta Pharmaceuticals
  • Class Antipsychotics; Indoles; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase Unknown Attention-deficit hyperactivity disorder; Gilles de la Tourette's syndrome

Most Recent Events

  • 20 Jun 2008 Investigation in Attention-deficit hyperactivity disorder in USA (PO)
  • 20 Jun 2008 Investigation in Gilles de la Tourette's syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top